Esposito Susanna, Puntoni Matteo, Deolmi Michela, Ramundo Greta, Maglietta Giuseppe, Poeta Marco, Zampogna Stefania, Colomba Claudia, Suppiej Agnese, Cardinale Fabio, Bosis Samantha, Castagnola Elio, Midulla Fabio, Giaquinto Carlo, Giordano Paola, Biasucci Giacomo, Fainardi Valentina, Nunziata Francesco, Grandinetti Roberto, Condemi Anna, Raiola Giuseppe, Guarino Alfredo, Caminiti Caterina
Pediatric Clinic, University Hospital, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Clinical and Epidemiological Research Unit, University Hospital of Parma, Parma, Italy.
Front Immunol. 2025 Apr 9;16:1466201. doi: 10.3389/fimmu.2025.1466201. eCollection 2025.
This observational prospective longitudinal multicenter study examines the occurrence and characteristics of long COVID (LC) in the Italian pediatric population.
Conducted across 12 Pediatric Units in Italy from January to March 2022, the study involved 1129 children diagnosed with SARS-CoV-2 infection. Data were collected via self-administered questionnaires at 1-3 months, 3-6 months, and 6-12 months post-infection, with LC defined as symptoms persisting for at least 2 months and occurring 3 months post-diagnosis.
Results revealed that 68.6% of children reported at least one post-COVID symptom, with 16.2% experiencing LC. The most frequent symptoms included respiratory issues (43.4%), neurological and cognitive dysfunction (27.7%), gastrointestinal symptoms (22.1%), fatigue (21.6%), and sleep disturbances (18.8%). Age and gender differences were significant, with older children and females more prone to cardiovascular and neurological & cognitive dysfunction.
The study highlights that LC in children presents similarly to adults, though less frequently. The occurrence of LC was lower compared to adult populations, likely due to the generally milder course of COVID-19 in children. The findings underscore the need for targeted follow-up and support for affected children, especially considering the long-term persistence of symptoms. Further research is necessary to explore the impact of COVID-19 vaccines on pediatric LC and the effects of different SARS-CoV-2 variants. These insights are crucial for developing strategies to manage and mitigate long-term impacts in children recovering from COVID-19.
这项观察性前瞻性纵向多中心研究调查了意大利儿科人群中新冠后综合征(LC)的发生情况和特征。
该研究于2022年1月至3月在意大利的12个儿科病房进行,涉及1129名被诊断为感染SARS-CoV-2的儿童。在感染后1至3个月、3至6个月和6至12个月通过自行填写问卷收集数据,LC定义为症状持续至少2个月且在诊断后3个月出现。
结果显示,68.6%的儿童报告至少有一种新冠后症状,16.2%的儿童出现了LC。最常见的症状包括呼吸道问题(43.4%)、神经和认知功能障碍(27.7%)、胃肠道症状(22.1%)、疲劳(21.6%)和睡眠障碍(18.8%)。年龄和性别差异显著,年龄较大的儿童和女性更容易出现心血管以及神经和认知功能障碍。
该研究强调,儿童的LC表现与成人相似,但频率较低。与成人相比,LC的发生率较低,这可能是由于儿童感染新冠病毒后病程通常较轻。这些发现强调了对受影响儿童进行有针对性的随访和支持的必要性,特别是考虑到症状的长期持续存在。有必要进一步研究新冠疫苗对儿科LC的影响以及不同SARS-CoV-2变体的影响。这些见解对于制定管理和减轻新冠康复儿童长期影响的策略至关重要。